文章预览
【格局/趋势】MSQ-2020 China Biopharma Global Transactions and IPOs Reviews Greetings from MSQ Ventures! 2020 was a special year with all challenges. Fortunately, the global biopharma industry was growing strong, especially the China biopharma industry which has made a breakthrough year with strong capital investment in the private and public market, and global transactions of license in/out driven by local innovation-focused policies. Based on our team's research and the interviews with top industry experts in China, we prepared this 2020 China biopharma global transactions and IPOs review. As many forecast that 2021 will be a better year, we expect that the China biopharma industry in 2021 will keep the steady growth and will play a more integrated role for global new drug development. About MSQVentures (MSQ) MSQ is aNYC-based cross-border advisory firm that bri
………………………………
